Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HDV-insulin lispro (Diasome Pharmaceuticals)
- Development stage
- Unknown
- Lead developer
- Diasome Pharmaceuticals
- Modality
- Peptides, Nanoparticles → Drug Delivery Systems
- Administration
- Subcutaneous
01
Overview
HDV-insulin lispro is a hepatocyte-targeted formulation of insulin lispro developed by Diasome Pharmaceuticals for the treatment of Type 1 and Type 2 diabetes. The therapy utilizes Diasome's proprietary Hepatocyte Directed Vesicle (HDV) technology, which consists of small phospholipid vesicles (liposomes) containing a targeting molecule that directs the insulin to the liver's portal-hepatic axis. This mechanism is designed to mimic the natural physiological delivery of insulin to the liver, thereby restoring hepatic glucose metabolism and potentially reducing the risk of peripheral hypoglycemia compared to standard subcutaneous insulin. The formulation is currently being evaluated in the Phase 2b OPTI-2 clinical trial to assess its efficacy in mealtime glucose control.
- Other names
- HDV-Insulin LisproHepatocyte Directed Vesicle-enabled insulin lispro
02
Targets
IGF-1R (Insulin-like growth factor 1 receptor)INSR (Insulin receptor)SLC5A6 (Sodium-dependent multivitamin transporter)
Beyond the preview
Go deeper on HDV-insulin lispro (Diasome Pharmaceuticals).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HDV-insulin lispro (Diasome Pharmaceuticals).